Coro­na Vac­ci­na­tion Indicator

You can fol­low how the vac­ci­na­tion pro­gress­es in the area with the help of Soite’s coro­na vac­ci­na­tion indi­ca­tor, which is updat­ed on Mon­day afternoons.

Soite’s coro­na vac­ci­na­tion indicator

Those who have received their first dose

36,6%

21845

(total num­ber of peo­ple that will be giv­en access to the vac­cine in the area 59 728)

Updat­ed: 3.5.2021

Groups to be vaccinated Sit­u­a­tion Time plan

Health and social care per­son­nel whose work is asso­ci­at­ed with the coronavirus.
Sup­ple­ment­ing vac­cines are giv­en accord­ing to need.

100%

Finished

FINISHED

Res­i­dents and per­son­nel at around-the-clock care home units for the elderly.
All res­i­dents have been vaccinated.

98%

Ongoing

Began 12.1.2021.

Per­sons above the age of 80 
Vac­cin: Pfiz­er-BioN­tec Comir­naty / Moderna

93%

Ongoing

Mass vaccinations began 4.2.2021

75–79-year-old per­sons
Vac­cin: Pfiz­er-BioN­tec Comir­naty / Mod­er­na / AstraZeneca

94%

Ongoing

Mass vaccinations began 3.3.2021.

70–74-year-old per­sons
Vac­cin: Pfiz­er-BioN­tec Comir­naty / Mod­er­na / AstraZeneca

88%

Ongoing

Mass vaccinations began 17.3.2021

Peo­ple aged 16–64 who belong to risk groups 1 and 2.
Vac­cin: Pfiz­er-BioN­tec Comir­naty / Mod­er­na (AstraZeneca)

77%

Ongoing

Mass vaccinations began 1.3.2021 for risk group 1 and 7.4.2021 for risk group 2.

65–69-year-old per­sons
Vac­cin: AstraZeneca

72%

Ongoing

Appointment booking opened 7.4.2021

60–64-year-old per­sons
Vac­cin: AstraZeneca

54%

Ongoing

Appointment booking opened 7.4.2021

55–59-year-old per­sons
Vac­cin: AstraZeneca

24%

Ongoing

Appointment booking opened 7.4.2021

Widescale vac­ci­na­tion of Soite’s social and health care per­son­nel and res­i­dents in Soite’s area

0%

Estimated to begin in the spring / summer of 2021

Link: Vac­ci­na­tions per area and age group (THL)

Risk group 1 under­ly­ing con­di­tions (more spe­cif­ic descrip­tions on the web­site of The Finnish Insti­tute for Health and Wel­fare THL)

• organ transplant or stem cell transplant
• people undergoing active cancer treatment
• severe disorders of the immune system
• severe chronic renal disease
• severe chronic pulmonary disease
• type 2 diabetes with medication
• Down syndrome

Risk group 2 under­ly­ing con­di­tions (more spe­cif­ic descrip­tions on the web­site of The Finnish Insti­tute for Health and Wel­fare THL)

• asthma requiring continuous medication
• severe heart disease e.g. heart failure (but not hypertension alone)
• neurological illness or condition that affects breathing
• immunosuppressive drug therapy for autoimmune disease
• severe chronic liver disease
• type 1 diabetes or adrenal insufficiency
• sleep apnoea
• psychosis
• morbid obesity (body mass index more than 40)